Selective peroxisome proliferator-activated receptor-γ modulation to reduce cardiovascular risk in patients with insulin resistance

Recent Patents on Cardiovascular Drug Discovery

Volumn 7, Issue 1, 2012, Pages 33-41

  Yew, Tongwei ^a   Toh, Sue Anne ^a,b   Millar, John S ^b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Int131; Metabolic syndrome; PPAR gamma; Spparm; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FK 614; GLUCOSE; GW 0072; INCRETIN; INT 131; KR 62980; LIPID; METAGLIDASEN; METFORMIN; MK 0533; PA 082; PAM 1616; PAR 1622; PAT 5A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; S 26948; SELECTIVE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA MODULATOR; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG EFFICACY; EDEMA; FLUID RETENTION; FRACTURE; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT GAIN;

ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE II AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; HUMANS; INSULIN RESISTANCE; PPAR GAMMA; QUINOLINES; SULFONAMIDES;

EID: 84857716778     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489012799362359     Document Type: Article

References (74)

1. Shulman AI, Mangelsdorf DJ. Retinoid X receptor heterodimers in the metabolic syndrome. N Engl J Med 2005; 353: 604-15.
2. Yang W, Rachez C, Freedman LP. Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators. Mol Cell Biol 2000; 20: 8008-17.
3. Higgins LS, Mantzoros CS. The development of INT131 as a selective PPARgamma modulator: Approach to a safer insulin sensitizer. PPAR Res 2008; 2008: 936906.
4. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: Opening the X-files. Science 2001; 294: 1866-70.
5. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005; 123: 993-9.
6. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-6.
7. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007; 1771: 1065-81.
8. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011; 342: d1309.
9. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
10. Yaturu S. Diabetes and skeletal health. J Diabetes 2009; 1: 246-54.
11. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP, Jr., et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-22.
12. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999; 1: 330-9.
13. Cohen SM. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci 2005; 87: 322-7.
14. [U.S. Federal Drug Administration. FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm (Accessed on: September 13, 2011).
15. [European Medicines Agency. European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/07/WC500109176.pdf (Accessed on: September 13, 2011).
16. Motani A, Wang Z, Weiszmann J, McGee LR, Lee G, Liu Q, et al. INT131: A selective modulator of PPAR gamma. J Mol Biol 2009; 386: 1301-11.
17. Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, et al. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 1999; 96: 6102-6.
18. Sheu SH, Kaya T, Waxman DJ, Vajda S. Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping. Biochemistry 2005; 44: 1193-209.
19. Cock TA, Houten SM, Auwerx J. Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm. EMBO Rep 2004; 5: 142-7.
20. Ge K, Guermah M, Yuan CX, Ito M, Wallberg AE, Spiegelman BM, et al. Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis. Nature 2002; 417: 563-7.
21. Picard F, Gehin M, Annicotte J, Rocchi S, Champy MF, O'Malley BW, et al. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 2002; 111: 931-41.
22. Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, Kochar A, et al. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low highdensity lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 624-30.
23. Szapary PO, Bloedon LT, Samaha FF, Duffy D, Wolfe ML, Soffer D, et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 182-8.
24. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi- Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005; 366: 1279-89.
25. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB, Sr., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: A randomized trial. JAMA 2006; 296: 2572-81.
26. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-73.
27. Schernthaner G and Chilton RJ. Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us? Diabetes Obes Metab 2010; 12: 1023-35.
28. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI and Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226-32.
29. Lebovitz HE. Differentiating members of the thiazolidinedione class: A focus on safety. Diabetes Metab Res Rev 2002; 18: S23-9.
30. Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, Mais DE, et al. A selective peroxisome proliferator-activated receptorgamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol 2000; 14: 1425-33.
31. Meegan MJ, Lloyd DG. Advances in the science of estrogen receptor modulation. Curr Med Chem 2003; 10: 181-210.
32. [Rangwala SM, Lazar MA. The dawn of the SPPARMs? Sci STKE 2002; 2002: pe9.
33. Clarke BL, Khosla S. New selective estrogen and androgen receptor modulators. Curr Opin Rheumatol 2009; 21: 374-9.
34. Nolan JJ, Jones NP, Patwardhan R and Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus. Diabet Med 2000; 17: 287-94.
35. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23: 1605-11.
36. Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 2001; 56: 239-63.
37. Kim MK, Chae YN, Choi SH, Moon HS, Son MH, Bae MH, et al. PAM-1616, a selective peroxisome proliferator-activated receptor gamma modulator with preserved anti-diabetic efficacy and reduced adverse effects. Eur J Pharmacol 650: 673-81.
38. Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, et al. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention. Arch Pharm Res 2009; 32: 721-7.
39. Sohn KA, Cruciani-Guglielmacci C, Kassis N, Clement L, Ouali F, Cauzac M, et al. S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats. Eur J Pharmacol 2009; 608: 104-11.
40. [Clinical Trials gov. Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00543959 (Accessed on: September 13, 2011).
41. Meinke PT, Wood HB, Szewczyk JW. Nuclear hormone receptor modulators for the treatment of diabetes and dyslipidemia. Ann Rep Med Chem 2006; 41: 99-126.
42. Cain C. Resolving the PPARγ paradox. Science Business Exchange 2010; 1-3.
43. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 2000; 106: 467-72.
44. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: From orphan receptors to drug discovery. J Med Chem 2000; 43: 527-50.
45. McGee LR, Rubenstein SM, Houze JB, Ye G, Li Y, Learned RM, et al. Discovery of AMG 131: A selective modulator of PPAR-γ. 231st American Chemical Society National Meeting. Atlanta, USA 2006.
46. DePaoli AM, Higgins LS. INT131, a non-TZD selective PPARγ modulator (SPPARM), does not cause toxicities typical of TZD full PPARγ agonists following 6-month high dose treatment of rats or monkeys. Diabetologia 2008; 52: 922 (abstract).
47. Dunn FL, Higgins LS, Fredrickson J, DePaoli AM. Selective modulation of PPARgamma activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. J Diabetes Complications 2011; 25: 151-8.
48. Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 2000; 60: 1245-50.
49. DePaoli AM, Dunn F, Pakele P, Mantzoros C, Higgins L. INT131 besylate, a selective PPARγ modulator (SPPARM), improved glycemic control in patients with type 2 diabetes without causing the edema seen with pioglitazone. Annual Meeting of the American Diabetes Association. Orlando, USA 2010.
50. Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, Laznik D, et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010; 466: 451-6.
51. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005; 437: 759-63.
52. Liu B, Shuai K. Targeting the PIAS1 SUMO ligase pathway to control inflammation. Trends Pharmacol Sci 2008; 29: 505-9.
53. Lim S, Ahn BY, Chung SS, Park HS, Cho BJ, Kim M, et al. Effect of a peroxisome proliferator-activated receptor gamma sumoylation mutant on neointimal formation after balloon injury in rats. Atherosclerosis 2009; 206: 411-7.
54. Plutzky J. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ Res 2011; 108: 1002-16.
55. Akar C, Kalinin S, Gavrilyuk V, Spagnolo A, Weinberg G, Feinstein D. Receptor-independent metabolic effects of thiazolidinediones in astrocytes. Open Cancer Immunol J 2010; 3: 36-40.
56. McDonald WG, Cole SL, Finck BN, Holewa DD, Brightwell- Conrad AS, Mackenzie CD, et al. Enhancement of brown adipose tissue development in vivo by a novel insulin sensitizer. Annual Meeting of the American Diabetes Association. San Diego, USA 2011.
57. Seed, B., Mechanic, J. Therapeutic uses of SGLT2 inhibitors. US20110077212 (2011).
58. Lanfear, D., Higgins, L. Combination of a selective PPAR-gamma modulator and an incretin for the treatment of diabetes and obesity. US20110034380 (2011).
59. Kahn BB, McGraw TE. Rosiglitazone, PPARgamma, and type 2 diabetes. N Engl J Med 2010; 363: 2667-9.
60. Higgins LS, Depaoli AM. Selective peroxisome proliferatoractivated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr 91: 267S-72S.
61. Hindley, R.M. Novel compounds. US5002953 (1991).
62. Meguro, K., Fujita, T. Thiazolidinedione derivatives, useful as antidiabetic agents. US4687777 (1987).
63. Minoura H, Takeshita S, Yamamoto T, Mabuchi M, Hirosumi J, Takakura S, et al. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat. Eur J Pharmacol 2005; 519: 182-90.
64. Yamasaki, N., Imoto, T., Murai, Y., Hiramura, T., Oku, T., Sawada, K. Benzimidazole derivatives. US6166219 (2000).
65. McGee, L.R., Houze, J.B., Rubenstein, S.M., Hagiwara, A., Furukawa, N., Shinkai, H. Quinolinyl and benzothiazolyl modulators. US6583157 (2003).
66. Chandalia A, Clarke HJ, Clemens LE, Pandey B, Vicena V, Lee P, et al. MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-gamma agonist lowers triglyceride independently of PPARalpha activation. PPAR Res 2009; 2009: 706852.
67. Luskey, K., Luo, J. Use of (-) (3-trihalomethylphenoxy) (4- halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia. US6262118 (2001).
68. Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, et al. A novel selective peroxisome proliferator-activator receptorgamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects. Eur J Pharmacol 2008; 584: 192-201.
69. Acton JJ, 3rd, Akiyama TE, Chang CH, Colwell L, Debenham S, Doebber T, et al. Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl) carbonyl]-2-methyl-6-(trifluoromethoxy)-1H- indol-1-yl}phenoxy) butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume. J Med Chem 2009; 52: 3846-54.
70. Liu, K., Meinke, P.T., Wood, H.B. Indoles having anti-diabetic activity. US7625933 (2004).
71. Carmona MC, Louche K, Lefebvre B, Pilon A, Hennuyer N, Audinot- Bouchez V, et al. S 26948: A new specific peroxisome proliferator activated receptor gamma modulator with potent antidiabetes and antiatherogenic effects. Diabetes 2007; 56: 2797-808.
72. Burgermeister E, Schnoebelen A, Flament A, Benz J, Stihle M, Gsell B, et al. A novel partial agonist of peroxisome proliferatoractivated receptor-gamma (PPARgamma) recruits PPARgammacoactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol Endocrinol 2006; 20: 809-30.
73. Mamidi RN, Katneni K, Mullangi R, Ramanujam R. Oral bioavailability and pharmacokinetics of PAT-5A, a new insulin sensitizer in rats. Eur J Drug Metab Pharmacokinet 2002; 27: 175-8.
74. Kim KR, Lee JH, Kim SJ, Rhee SD, Jung WH, Yang SD, et al. KR-62980: A novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects. Biochem Pharmacol 2006; 72: 446-54.